Le produit a bien été ajouté au panier.

discount label
H-SNWKWWPGIFD-OH
Vue en 3D

Biosynth logo

H-SNWKWWPGIFD-OH

Ref. 3D-PP48217

1mg
268,00 €
10mg
315,00 €
100mg
519,00 €
Livraison estimée en/au États-Unis, le jeudi 27 mars 2025

Informations sur le produit

Nom :
H-SNWKWWPGIFD-OH
Description :

Peptide H-SNWKWWPGIFD-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SNWKWWPGIFD-OH include the following: Detection of polyglutamine protein oligomers in cells by fluorescence correlation spectroscopy Y Takahashi, Y Okamoto, HA Popiel, N Fujikake - Journal of Biological , 2007 - ASBMBhttps://www.jbc.org/article/S0021-9258(20)54387-1/abstract A toxic monomeric conformer of the polyglutamine protein Y Nagai , T Inui , HA Popiel, N Fujikake - Nature structural & , 2007 - nature.comhttps://www.nature.com/articles/nsmb1215 Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Y Nagai , N Fujikake, K Ohno - Human molecular , 2003 - academic.oup.comhttps://academic.oup.com/hmg/article-abstract/12/11/1253/555306 Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis Y Nagai , HA Popiel - Current pharmaceutical design, 2008 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2008/00000014/00000030/art00006 Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases Y Nagai - Rinsho Shinkeigaku= Clinical Neurology, 2009 - europepmc.orghttps://europepmc.org/article/med/20030247 By KIMBERLY L. SCIARRETTA, DAVID J. GORDON, and SC MEREDITH - Amyloid, Prions, and Other Protein Aggregates , 2006 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=JOOCnik5QNAC&oi=fnd&pg=PA273&dq=(%22SNWKWWPGIFD%22+OR+%22H-SNWKWWPGIFD-OH%22)+AND+peptide&ots=uyQl_6UaVU&sig=PGgYTPFhVZDdFJW-mTNmJjJF2SE Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases RS Armen, BM Bernard, R Day - Proceedings of the , 2005 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0502068102 Brain-targeting delivery of two peptidylic inhibitors for their combination therapy in transgenic polyglutamine disease mice via intranasal administration M Yang , Q Zhang , Q Wang, KK Sorensen - Molecular , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.8b00938 Peptide-based inhibitors of amyloid assembly KL Sciarretta, DJ Gordon , SC Meredith - Methods in enzymology, 2006 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0076687906130153 Making protein interactions druggable: targeting PDZ domains KK Dev - Nature reviews Drug discovery, 2004 - nature.comhttps://www.nature.com/articles/nrd1578 Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice HA Popiel, Y Nagai , N Fujikake, T Toda - Neuroscience letters, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0304394008008288 Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases HA Popiel, T Takeuchi, JR Burke, WJ Strittmatter - , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1878747923012345 Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death H Ren, Y Nagai , T Tucker, WJ Strittmatter - Biochemical and , 2001 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006291X01957833 Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins H Naiki , Y Nagai - Journal of biochemistry, 2009 - academic.oup.comhttps://academic.oup.com/jb/article-abstract/146/6/751/807596 Identifying new therapeutics for Huntington's disease G Schilling, DR Borchelt - Clinical Neuroscience Research, 2003 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1566277203000604 Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors BA Margulis, V Vigont, VF Lazarev, EV Kaznacheyeva - FEBS letters, 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0014579313003657

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP48217 H-SNWKWWPGIFD-OH

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

  • Choisissez l’indicatif du pays du téléphone.
  • Spain (España)+34
  • Portugal+351
  • Germany (Deutschland)+49
  • France+33
  • Italy (Italia)+39
  • Afghanistan (‫افغانستان‬‎)+93
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1
  • Andorra+376
  • Angola+244
  • Anguilla+1
  • Antigua and Barbuda+1
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1
  • Bahrain (‫البحرين‬‎)+973
  • Bangladesh (বাংলাদেশ)+880
  • Barbados+1
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1
  • Guadeloupe+590
  • Guam+1
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Iran (‫ایران‬‎)+98
  • Iraq (‫العراق‬‎)+964
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Macedonia (FYROM) (Македонија)+389
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Nepal (नेपाल)+977
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • North Korea (조선 민주주의 인민 공화국)+850
  • Northern Mariana Islands+1
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Pakistan (‫پاکستان‬‎)+92
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1
  • Saint Lucia+1
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Swaziland+268
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1
  • Tuvalu+688
  • U.S. Virgin Islands+1
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358
  • Choisissez l’indicatif du pays du téléphone.
* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".